|
Incyte Corporation: Premium Company ProfilePublished by: Datamonitor Published: Apr. 22, 2008 - 45 Pages Table of Contents
AbstractIntroductionIncyte is a development stage company involved in drug discovery and development activities with major focus on developing small molecule drugs to treat various diseases. The company has proprietary product pipeline in various stages of development for the treatment of oncology, inflammation, diabetes and HIV. Scope Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies Highlights Incyte operates in one segment, biotechnology drug discovery and development. The company’s proprietary pipeline programs in various stages of development include: Janus-associated Kinase 2 (JAK 2) program for inflammation, hematologic malignancies, and solid tumors; Incyte’s total revenues decreased at a CAGR of 27% from $95 million to $28 million during the historical period 2002-2006. The company derived revenues solely from royalties, license fee and collaboration. During 2006-2010, Incyte’s forecast revenues would decrease at a CAGR of 5% from $28 million to $23 million, likely due to the diminishing market for information products. Reasons to Purchase Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization . Please note: This is delivered as a Zip file. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||